Research library
The research library
Every primary source behind a claim on this site, tier-graded for provenance and tagged for the strength of the evidence it carries.
- Sources indexed
- 221
- Peptides covered
- 44
- Tier 1 share
- 25%
- Matching filter
- 4
F·Filter
Reset allT1·Peer-primary literature
Randomized trials, peer-reviewed primary studies, and meta-analyses — the load-bearing layer of the corpus.
1 source
- 2010Meta-analysisstrongn=806
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Falutz J, Mamputu JC, Potvin D, +6 · Journal of Clinical Endocrinology & Metabolism
Pooled across two phase 3 trials in 806 ART-treated HIV patients with abdominal fat accumulation, tesamorelin reduced visceral adipose tissue and maintained the reduction for 52 weeks while preserving subcutaneous fat — the extended-evidence companion to the 2007 NEJM pivotal.
T2·Peer-secondary literature
Peer-reviewed reviews and cohort/observational work — context, not bedrock.
3 sources
- 2023Meta-analysisstrongn=1,773
Cerebrolysin for acute ischaemic stroke
Ziganshina LE, Abakumova T, Nurkhametova D, +1 · Cochrane Database of Systematic Reviews
The 2023 Cochrane review pooled seven trials and 1,773 participants and concluded with moderate-certainty evidence that Cerebrolysin probably has little to no effect on all-cause death after acute ischemic stroke — the load-bearing skeptical reading of the trial body.
- 2019Meta-analysisstrong
The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: a systematic review and meta-analyses
Mayhew AJ, Amog K, Phillips S, +5 · Age and Ageing
Across 109 articles, 58 cohorts, and 26 countries, sarcopenia prevalence ranged from 9.9% to 40.4% depending on the diagnostic definition applied — a four-fold spread driven by methodology rather than biology.
- 1995Meta-analysisstrong
The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis
Lijesen GK, Theeuwen I, Assendelft WJ, +1 · British Journal of Clinical Pharmacology
A criteria-based meta-analysis of 24 HCG-for-obesity trials found that 11 of the 12 methodologically adequate studies reported no effect of HCG on weight loss, fat redistribution, hunger, or sense of well-being — the load-bearing negative result behind the modern medical consensus that the Simeons HCG diet does not work.